| Renal Cell Carcinoma
Afinitor vs Welireg
Side-by-side clinical, coverage, and cost comparison for renal cell carcinoma.Deep comparison between: Afinitor vs Welireg with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsWelireg has a higher rate of injection site reactions vs Afinitor based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Welireg but not Afinitor, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Afinitor
Welireg
At A Glance
Oral
Daily
mTOR inhibitor
Oral
Once daily
HIF-2α inhibitor
Indications
- Hormone receptor positive breast cancer
- Neuroendocrine tumor of pancreas
- Gastro-enteropancreatic neuroendocrine tumor
- Renal Cell Carcinoma
- Angiomyolipoma of kidney
- Subependymal Giant Cell Astrocytoma
- Seizures, Focal
- Von Hippel-Lindau Syndrome
- Renal Cell Carcinoma
- Pheochromocytoma
- Paraganglioma
Dosing
Hormone receptor positive breast cancer 10 mg orally once daily in combination with exemestane until disease progression or unacceptable toxicity.
Neuroendocrine tumor of pancreas, Gastro-enteropancreatic neuroendocrine tumor 10 mg orally once daily until disease progression or unacceptable toxicity.
Renal Cell Carcinoma 10 mg orally once daily until disease progression or unacceptable toxicity.
Angiomyolipoma of kidney 10 mg orally once daily until disease progression or unacceptable toxicity.
Subependymal Giant Cell Astrocytoma Starting dose 4.5 mg/m2 orally once daily (AFINITOR or AFINITOR DISPERZ); titrate to trough concentration 5-15 ng/mL.
Seizures, Focal Starting dose 5 mg/m2 orally once daily (AFINITOR DISPERZ); titrate to trough concentration 5-15 ng/mL.
Von Hippel-Lindau Syndrome Adults: 120 mg orally once daily. Pediatric patients >=12 years: 120 mg orally once daily if >=40 kg or 80 mg orally once daily if <40 kg.
Renal Cell Carcinoma Adults: 120 mg orally once daily.
Pheochromocytoma Adults: 120 mg orally once daily. Pediatric patients >=12 years: 120 mg orally once daily if >=40 kg or 80 mg orally once daily if <40 kg.
Paraganglioma Adults: 120 mg orally once daily. Pediatric patients >=12 years: 120 mg orally once daily if >=40 kg or 80 mg orally once daily if <40 kg.
Contraindications
- Clinically significant hypersensitivity to everolimus or other rapamycin derivatives
—
Adverse Reactions
Most common (>=30%) Stomatitis, infections, rash, fatigue, diarrhea, decreased appetite.
Serious Non-infectious pneumonitis, infections, severe hypersensitivity reactions, angioedema, stomatitis, renal failure, impaired wound healing, metabolic disorders (hyperglycemia, dyslipidemia), myelosuppression, radiation sensitization and recall.
Postmarketing Thrombotic microangiopathy, cardiac failure (including with pulmonary hypertension), acute pancreatitis, cholecystitis, cholelithiasis, sepsis, reflex sympathetic dystrophy, arterial thrombotic events, lymphedema, radiation sensitization and recall.
Most common (>=25%) Decreased hemoglobin, fatigue, increased creatinine, headache, dizziness, increased glucose, nausea, musculoskeletal pain, decreased lymphocytes, increased alanine aminotransferase, decreased sodium, increased potassium, increased aspartate aminotransferase, anemia, dyspnea, increased calcium, decreased leukocytes, increased alkaline phosphatase.
Serious Anemia, hypoxia, hemorrhage, pneumonia, pleural effusion, pyelonephritis, hypertension, retinal detachment, central retinal vein occlusion, anaphylaxis reaction.
Postmarketing Not reported in label.
Pharmacology
Everolimus is an mTOR inhibitor that binds the intracellular protein FKBP-12 to form an inhibitory complex with mTORC1, suppressing downstream effectors (S6K1, 4E-BP1) involved in protein synthesis, cell proliferation, and angiogenesis, and reducing HIF-1 and VEGF expression; mTOR pathway dysregulation occurs in several human cancers and in tuberous sclerosis complex.
Belzutifan is a hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor that binds to HIF-2α and blocks its interaction with HIF-1β, leading to reduced transcription of HIF-2α target genes associated with cellular proliferation, angiogenesis, and tumor growth.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Afinitor
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (0/12)
Welireg
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Afinitor
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (6/8)
Welireg
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Afinitor
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (2/3)
Welireg
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Afinitor.
$5/fillfill
Welireg Co-Pay Coupon Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AfinitorView full Afinitor profile
WeliregView full Welireg profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.